Cel-Sci (NASDAQ:CVM) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cel-Sci (NASDAQ:CVM) in a research report report published on Monday morning, Zacks.com reports.

Shares of NASDAQ:CVM opened at $9.09 on Monday.

About Cel-Sci

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Featured Story: What is the float in trading stocks?

Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.